Current Edition

Can the regulators keep up with the
Volume 10 Issue 3

Can the Regulators Keep Up with the Emerging Digitalisation in Laboratories?

Laboratories constitute an essential part of any pharmaceutical company, as they are usually where the history of the company began. Without the scientific research taking …

Continue Reading →
Imprecise protection_Differing attitudes of
Volume 10 Issue 3

Imprecise Protection? Differing Attitudes of Global Patent Offices to Precision Medicine

While precision medicine is streaking ahead in its development and governments are willing to embrace the new treatment options it offers, patent offices are still …

Continue Reading →
EU falsifield medicines directive
Volume 10 Issue 3

EU Falsified Medicines Directive: The Requirements

Manufacturers of pharmaceutical goods are required to identify all products with a 2D data matrix code and add tamper-evidence labelling. A much less forgiving verifier …

Continue Reading →
How to develop integrated drug delivery
Volume 10 Issue 3

How to Develop Integrated Drug Delivery Systems to Meet Patient Needs

The field of integrated drug delivery is rapidly changing. Today’s patients are empowered, knowledgeable and seeking treatment on their own terms, often outside of healthcare …

Continue Reading →
A placebo controlled clinical study to evaluate
Volume 10 Issue 3

A Placebo-controlled Clinical Study to Evaluate the Efficacy & Safety of Instavit® Sweet Dreams Oral Spray in the Treatment of Occasional Sleeplessness

New Instavit® Sweet Dreams is a melatonin-based oral spray supplement that has been physician-formulated. It is designed to promote a natural sleep cycle and a …

Continue Reading →
R&D trends in the Asia Pacific
Volume 10 Issue 3

R&D Trends in the Asia-Pacific

While pharmaceutical research continues to grow steadily, with a forecast compound annual growth rate of over 3% for 2015–2020, the untold story may be the …

Continue Reading →
Subject recruitment and retention
Volume 10 Issue 3

Subject Recruitment and Retention for Clinical Trial Success

Professor Christene Leiper of Onorach identifies why it is crucial from the outset when planning a clinical trial to have an adequate sample size. Recruiting …

Continue Reading →
The second age of digital and the rise
Volume 10 Issue 3

The Second Age of Digital and the Rise of the Multichannel Rep

As digital continues to permeate the life sciences industry, it is having a transformative impact on commercial organisations’ ability to engage their many stakeholders, from …

Continue Reading →
Breaking down barriers to digital advancement
Volume 10 Issue 3

Breaking Down Barriers to Digital Advancement in Life Sciences R&D

Life sciences organisations must be clear what they are aiming for if they are to fully exploit the opportunities offered by digital technologies, yet disconnected …

Continue Reading →
Serialisation and data connectivity
Volume 10 Issue 3

Serialisation and Data Connectivity – the New Wrinkle in your Supply Chain

Ben Jones of PCI Pharma Services explores the attractiveness of the US drug market for selling pharmaceutical therapies. With a population of more than 330 …

Continue Reading →